Business
Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas
Company delivers on ambitious clinical development goal with four ongoing clinical trials in 2022 SAN FRANCISCO, May 17, 2022 (GLOBE NEWSWIRE) -- Nurix
About this update from Nurix Therapeutics, Inc.
[{"type":"text","content":"Company delivers on ambitious clinical development goal with four ongoing clinical trials in 2022\nSAN FRANCISCO, May 17, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the first patient has been dosed in its Phase 1a/1b study to evaluate orally available small molecule NX-5948, a potent and selective degrader of Bruton’s tyrosine kinase (BTK) in patients with relapsed B-cell malignancies. Nurix is conducting the open-label, dose escalation and expansion trial at multiple centers in the United Kingdom. The trial is designed to evaluate the safety and tolerability of NX-5948 in adults with relapsed or refractory B-cell malignancies. Nurix expects to have initial safety and pharmacokinetic and pharmacodynamic data from the Phase 1a portion of the study in the second half of 2022. “We are excited to have initiated the trial of a second highly selective and potent BTK degrader, that has the additional feature of being able to cross the blood brain barrier,” said Robert J. Brown, M.D., executive vice president of clinical development of Nurix. “NX-5948 has the potential to offer a differentiated clinical profile for patients with relapsed or refractory B cell malignancies.” In preclinical studies presented at the 2021 American Society of Hematology (ASH) Annual Meeting, NX-5948 demonstrated potent anti-tumor activity in models of both ibrutinib-sensitive and ibrutinib-resistant (C481S mutant BTK) lymphoma. NX-5948 was able to cross the blood brain barrier in preclinical models, degrade BTK in both microglia and central nervous system (CNS) resident lymphoma cells, and exert anti-lymphoma activity in a model of primary central nervous system lymphoma (PCNSL). “Our BTK degraders, NX-2127 and NX-5948, provide potentially complementary solutions to the growing problem of resistance, which has been noted with all BTK inhibitors currently in use and leads to disease relapse,” stated Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. “Our ongoing clinical trials of these two differentiated molecules, NX-2127, with additional cereblon immunomodulatory activity, and NX-5948 which is central nervous system penetrant, are expected to provide key data that will inform each molecule’s optimal ...